CD274 and B-cell chronic lymphocytic leukemia: Several studies reported the dysregulation of PD1/PD-L1 axis in CLL; however, even though preclinical data suggested that patients with CLL may take advantage from PD-1/PD-L1 blockade, no clinical benefit was achieved in clinical trials [30,31].